Allspring Global Investments
NRIX icon

Allspring Global Investments’s Nurix Therapeutics NRIX Stock Holding History

Allspring Global Investments’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$208K Buy
+13,410
New +$222K ﹤0.01% 1602
2025
Q1 		– Sell
-89,920
Closed -$1.69M – 1791
2024
Q4 		$1.69M Sell
89,920
-50,353
-36% -$1.15M ﹤0.01% 1181
2024
Q3 		$3.15M Buy
+140,273
New +$3.18M ﹤0.01% 1059
2024
Q1 		– Sell
-1,018
Closed -$10.5K – 2369
2023
Q4 		$10.5K Sell
1,018
-217
-18% -$1.49K ﹤0.01% 2019
2023
Q3 		$9.71K Sell
1,235
-4,029
-77% -$36.8K ﹤0.01% 2611
2023
Q2 		$52.6K Buy
5,264
+4,036
+329% +$41.2K ﹤0.01% 2280
2023
Q1 		$10.9K Buy
1,228
+327
+36% +$3.41K ﹤0.01% 2587
2022
Q4 		$9.89K Sell
901
-20
-2% -$241 ﹤0.01% 2715
2022
Q3 		$12K Sell
921
-642
-41% -$10.2K ﹤0.01% 2705
2022
Q2 		$19K Sell
1,563
-5,611
-78% -$63.6K ﹤0.01% 2499
2022
Q1 		$100K Buy
7,174
+994
+16% +$17.6K ﹤0.01% 2749
2021
Q4 		$178K Buy
+6,180
New +$187K ﹤0.01% 2654

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Allspring Global Investments's NRIX Position: Q1 2026 in Review

Allspring Global Investments opened a new position in Nurix Therapeutics (NRIX) in Q1 2026: 13,410 shares worth $208K. The stake represents ﹤0.01% of the portfolio and ranks #1602 among its holdings. This is a return to the name: Allspring Global Investments previously reported a position in NRIX as recently as Q4 2024.

Allspring Global Investments first reported a position in NRIX in Q4 2021 and has held it in 12 quarters since. The position peaked at $3.15M in Q3 2024. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Allspring Global Investments held 13,410 shares of Nurix Therapeutics worth $208K as of Q1 2026.
  • Nurix Therapeutics was a new Allspring Global Investments position in Q1 2026.
  • Nurix Therapeutics made up ﹤0.01% of Allspring Global Investments's portfolio in Q1 2026, its #1602 holding.
  • Allspring Global Investments first reported a position in Nurix Therapeutics in Q4 2021 and has held it in 12 quarters since.
  • Allspring Global Investments's Nurix Therapeutics position peaked at $3.15M in Q3 2024.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Allspring Global Investments's 13F filing for Q1 2026, filed 5 May 2026.